RxDoctor Payments Data

Azra Abdullah, MD

Family Medicine · Indianapolis, INNPI 1063468916

Payments from drug & device makers

$2,199in general payments, 2019–2025

Across 136 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$457
  • Lilly USA, LLC$262
  • Novo Nordisk$225
  • GSK$193
  • Amarin Pharma, Inc.$125
  • Pfizer$120
  • plus $816 from 19 others

What the payments were for

  • Food & beverage$2,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,199 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$49,431
Medicare patients
130
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$176,391
JardianceEmpagliflozin131$128,580
TrulicityDulaglutide41$59,436
MounjaroTirzepatide39$44,249
Janumet XrSitagliptin Phos/Metformin Hcl17$25,813
Breo ElliptaFluticasone/Vilanterol29$17,070
Tresiba Flextouch U-100Insulin Degludec20$15,386
Spiriva RespimatTiotropium Bromide12$14,913
MyrbetriqMirabegron20$13,274
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$12,921
JanumetSitagliptin Phos/Metformin Hcl19$11,839
TradjentaLinagliptin11$9,937
FarxigaDapagliflozin Propanediol11$8,525
ShingrixVaricella-Zoster Ge/As01b/Pf37$8,225
Diclofenac Epolamine13$7,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$225$176,391129 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$50$153,430154 claims
Lilly USA, LLCTrulicity, Mounjaro$262$103,68580 claims
MerckJanumet Xr, Janumet$41$37,65236 claims
GSKBreo Ellipta, Shingrix$193$25,29566 claims
AstraZenecaFarxiga, Symbicort$457$14,03727 claims
Astellas Pharma US IncMyrbetriq$85$13,27420 claims
PfizerAbrysvo$120$4,09713 claims
AbbVieSynthroid$26$3,29350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →